Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 25 Advanced Solid Tumors 18 Breast Neoplasms 12 Myelodysplastic Syndromes 11 Neoplasms 10 Advanced Solid Tumor 10 Prostatic Neoplasms 9 Solid Tumor 7 Neoplasm Metastasis 7 Multiple Myeloma 7 Recurrence 6 Carcinoma, Non-Small-Cell Lung 6 Pancreatic Neoplasms 5 Colorectal Neoplasms 5 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Melanoma 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia 4 Solid Tumors 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Ovarian Neoplasms 3 Lung Neoplasms 3 Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 2 Primary Myelofibrosis 2 Nasopharyngeal Carcinoma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2

Interventions

pembrolizumab 1 SH-1028 1 Injections 1 2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Solid Cancer × Injections × Clear all

NCT07265921 2025-12-05

Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡